| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 630 companies in the Biotechnology industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | REGN Regeneron Pharmaceuticals, Inc. | Ryan Arthur F54 | Director | Sell | 100 | $705.24 | $70,523.80 | - | - | - | |
| May 1, 2026 | NTHI Neonc Technologies Holdings, Inc. | Heshmatpour Amir F | President | Buy | 10,000 | $4.16 | $41,592.00 | +0.3% | - | - | |
| May 1, 2026 | XERS Xeris Biopharma Holdings, Inc. | Hecht Beth47 | See Remarks | Sell | 16,667 | $6.23 | $103,805.41 | -1.4% | - | - | |
| Apr 30, 2026 | NRIX Nurix Therapeutics, Inc. | Van Houte Hans60 | Chief Financial Officer | Sell | 2,388 | $16.65 | $39,748.98 | -4.4% | - | - | |
| Apr 30, 2026 | NRIX Nurix Therapeutics, Inc. | Ring Christine77 | Chief Legal Officer | Sell | 3,214 | $16.65 | $53,497.99 | -9.2% | - | - | |
| Apr 30, 2026 | NRIX Nurix Therapeutics, Inc. | Hansen Gwenn73 | Chief Scientific Officer | Sell | 3,214 | $16.65 | $53,497.99 | -2.6% | - | - | |
| Apr 30, 2026 | PHVS Pharvaris N.V. | Lesage Anne | Chief Early Development | Sell | 48,300 | $30.23 | $1,459,970.16 | -9.6% | - | - | |
| Apr 30, 2026 | PHVS Pharvaris N.V. | Schikan Johannes Gerardus Christiaan Petrus | Director | Sell | 32,900 | $30.29 | $996,544.70 | -2.9% | - | - | |
| Apr 30, 2026 | PHVS Pharvaris N.V. | Lu Peng | Chief Medical Officer | Sell | 18,733 | $30.21 | $565,859.27 | -12.7% | - | - | |
| Apr 29, 2026 | KYMR Kymera Therapeutics, Inc. | Mainolfi Nello70 | Chief Executive Officer | Sell | 30,000 | $81.18 | $2,435,377.20 | -1.5% | - | - | |
| Apr 29, 2026 | BCDA Biocardia, Inc. | Altman Peter46 | President And CEO | Buy | 5,000 | $1.11 | $5,550.00 | +1.8% | - | - | |
| Apr 29, 2026 | TLPPF Telix Pharmaceuticals Limited | Behrenbruch Christian | MD &Group CEO | Buy | 67,935 | $14.67 | $996,738.45 | +0.2% | - | - | |
| Apr 29, 2026 | ZBIO Zenas Biopharma, Inc. | Moulder Leon O Jr79 | Chief Executive Officer | Buy | 60,000 | $17.79 | $1,067,200.00 | +1.7% | - | - | |
| Apr 29, 2026 | HOWL Werewolf Therapeutics, Inc. | Evnin Luke55 | Director | Sell | 205,911 | $0.75 | $154,525.47 | -3.3% | - | - | |
| Apr 28, 2026 | NTHI Neonc Technologies Holdings, Inc. | Heshmatpour Amir F | President | Buy | 10,000 | $4.52 | $45,180.00 | +0.3% | - | - | |
| Apr 28, 2026 | RPRX Royalty Pharma Plc | Coyne Terrance P.75 | EVP &CFO | Sell | 34,791 | $49.78 | $1,731,840.31 | -46.4% | - | - | |
| Apr 28, 2026 | DYN Dyne Therapeutics, Inc. | Rhodes Jason P78 | Director | Sell | 227,337 | $18.38 | $4,178,516.06 | -1.5% | - | - | |
| Apr 28, 2026 | GILD Gilead Sciences, Inc. | O'Day Daniel Patrick | Chairman &CEO | Sell | 10,000 | $129.16 | $1,291,608.37 | -0.8% | - | - | |
| Apr 27, 2026 | NCEL Newcelx Ltd. | Revel Michel | CSO And Director | Buy | 54,545 | $2.75 | $149,998.75 | +6.0% | - | - | |
| Apr 27, 2026 | NCEL Newcelx Ltd. | Samuel Olivier | Director | Buy | 81,818 | $2.75 | $224,999.50 | New | - | - | |
| Apr 27, 2026 | BCAX Bicara Therapeutics Inc. | Raben David52 | Chief Medical Officer | Sell | 5,500 | $22.88 | $125,830.10 | -9.0% | - | - | |
| Apr 27, 2026 | OBIO Orchestra Biomed Holdings, Inc. | Rtw Investments, LP63 | 10% Owner | Sell | 32 | $4.13 | $132.16 | - | - | - | |
| Apr 27, 2026 | ADPT Adaptive Biotechnologies Corporation | Rubinstein Julie84 | President And COO | Sell | 19,037 | $14.23 | $270,896.51 | -4.8% | - | - | |
| Apr 27, 2026 | DYN Dyne Therapeutics, Inc. | Rhodes Jason P78 | Director | Sell | 384,549 | $18.47 | $7,101,119.51 | -1.6% | - | - | |
| Apr 24, 2026 | CGEN Compugen Ltd. | Levine Zurit | SVP, Business Development | Sell | 2,000 | $3.20 | $6,400.00 | -6.4% | - | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.